Story perspectives

New Intranasal DNA Vaccine Shows Promise Against Drug-Resistant TB

4/8/2026

Summary

Story summary

Researchers from Johns Hopkins Medicine developed an intranasal DNA vaccine targeting drug-tolerant tuberculosis by combining two genes.
In mouse studies, the vaccine accelerated bacterial clearance and reduced lung inflammation.
Primate studies showed durable immune responses, though further research is needed before human trials.
The study was published in the Journal of Clinical Investigation on April 1, 2026.
Researchers say the vaccine could complement existing treatments and address drug-resistant TB challenges.

1 of 1

Story summary

Researchers from Johns Hopkins Medicine developed an intranasal DNA vaccine targeting drug-tolerant tuberculosis by combining two genes.
In mouse studies, the vaccine accelerated bacterial clearance and reduced lung inflammation.
Primate studies showed durable immune responses, though further research is needed before human trials.
The study was published in the Journal of Clinical Investigation on April 1, 2026.
Researchers say the vaccine could complement existing treatments and address drug-resistant TB challenges.